The median age of patients with acute myeloid leukemia (AML) is around 70 years.
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Calendar age reflects an absolute value but it ignores the 'biological age' that is representative of the physical condition which may vary considerably among older people of the same age.
In any event, while old age as such is not a feature that defines a disease entity, it is of significant clinical relevance because it confers profound prognostic impact on disease outcome. Treatment outcome in patients with AML continuously declines with progressively increasing age. 2 Some of the key questions for clinical hematologists in daily practice are:
'Which patient at older age can receive intensive treatment and not experience prohibitive toxicity?' 'Secondly, even in those that can tolerate such chemotherapy, would disease features make the likelihood of benefit so low that non-intensive therapy would be a better option?'
In industrialized societies the average life expectancy at age 65 years is still around 15-20 years, which underscores the considerable lifetime that can be gained if AML at that age could be cured. Specific clinical trials have been dedicated to the older age segment of patients with the objective of improving their treatment outcome. Clinical trials for practical reasons have usually applied age cutoffs above age 60 to 70 years as operational definitions for older patients. Enrollment in such trials usually implies that the investigator assumes that the patient will tolerate intensive chemotherapy. On average a significant proportion of about 50-60% will successfully attain a complete remission (CR). However, such fairly high rates of good response translate into a two year survival of only of 15-20%
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. These outcome results have only very modestly improved in the last decade, in particular in patients below 75 yrs. 4, 5, 6 However, there is a significant individual heterogeneity that likely accounts for a substantial variation in treatment outcome among patients eg in relation to leukemia cytogenetics and molecular genetics. 3, 4 The determinants of success and failure nevertheless remain only partly understood.
These determinants are clearly multifold and include a combination of patient-related and specific disease-related factors. In this article we will present four selected clinical vignettes that highlight our treatment approach in clinical practice in light of the biology of the disease and we will discuss some of the common practical issues and dilemmas that we encounter in the therapeutic management of patients with AML at older age.
Which patient qualifies as candidate for intensive treatment?
Population data from the Swedish Acute Leukemia Registry suggest that the majority of older patients should be regarded as candidates for intensive chemotherapy. These national registry data show that generally older patients with AML fare markedly better on intensive chemotherapy than on palliative treatment. Performance status rather than age in the strict sense is predictive of early mortality. 10 ,11 Yet, a particular proportion of AML patients won't tolerate the use of intensive chemotherapy. Those patients may be offered demethylating agents (eg decitabine, azacitidine) as a less intensive modality of treatment. 12 The recognition of patients who might more likely benefit from an intensive treatment approach should ideally be based on baseline assessments. It is and has remained a challenge to identify those patients prior to the start of treatment and define their features. A variety of composite multifactorial risk algorithms have been proposed in which patient specific factors (performance, comorbidity scores) together with disease specific factors (cyto)genetics, white blood cell counts, percent marrow blast count, secondary leukemias) have been taken into account to predict treatment effectiveness and lend support to a documented choice between intensive treatment and various other treatment possibilities. [13] [14] [15] An inherent limitation of all these risk algorithms is that they have been derived from data of a patient population who had already been selected for intensive treatment and thus they do not reflect the average real world of As yet none of these risk algorithms have become widely accepted. However the decreased rate of treatment related mortality in intensively treated patients recently described could be partly explained by a better selection of patients suitable for this intensive therapy.
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Additional research on the developments of measurements solidly validated and preferably quite easily applicable in clinical practice is ongoing.
On the other hand particular disease-specific biological characteristics of AML may be associated with such a poor outcome that even though patients are considered to be medically fit, they will unlikely benefit from intensive treatment and therefore should perhaps rather be offered a less intensive or investigational approach. weeks, complete donor chimerism ensued with no apparent signs of graft-versus-host disease.
Mycophenolate was discontinued at 3 months and cyclosporin at 6 months. Currently the patient survives in good performance and remains disease free at 24 months after diagnosis.
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Comments about Patient 1
This patient illustrates that in a fit elderly patient with AML even with unfavorable risk characteristics and various comorbid conditions it may be useful to embark on a treatment plan with curative intent with intensive chemotherapy followed by an allogeneic transplant.
Clinicians with a treatment goal in mind that has been defined in advance, should obviously be prepared to adjust their plan according the course of medical developments. There is no basis for an absolute 'a priori' fatalism, even not when there are various unfavorable signs although a favorable outcome as described here will be relatively uncommon. This leukemia carried three types of adverse genomic abnormalities that each define poor outcome. 21 The AML exhibited chromosomal abnormalities additional to a single monosomy and thus fulfilled the criterium of a monosomal karyotype 25, 26 and the AML also exhibited high expression of the oncogene EVI1, a known unfavorable feature in younger adults with AML. 22 .Furthermore the loss of chromosome 17 also is a high-risk prognostic marker in AML. A recent analysis from an international study consortium has confirmed the generally poor outcome of patients with AML with various abnormalities that involve 17p and include -17, so called abn(17p), where the P53 gene is located. 27 If the direction towards intensive chemotherapy is chosen, the older patient deserves adequate dose intensified chemotherapy rather than a chemotherapy regimen with unsubstantiated dose level reductions. Nevertheless it is generally accepted that achieving CR is a first necessary positive step on the way to improved outcome. Survival beyond 3 years is unlikely if CR has not been achieved.
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Whenever possible it may make sense to try and lead these patients to an allogeneic HSCT in a way that is similar to the approach that is pursued in younger and middle-aged adults.
4,32,33
In a fraction of patients a CR may be achieved with demethylating agents. The use of these agents is associated with less toxicity and may also lead the way towards allogeneic HSCT rescue treatment. 12 In recent years allogeneic HSCT is more commonly applied at higher age since long term data indicates that allogeneic HSCT after reduced intensity conditioning is 
Comments about patient 2
This patient has an estimated prognosis that markedly contrasts from that of patient 1. He has AML with a relatively favorable genotype, ie a normal karyotype with biallelic mutant CEBPA. These 'favorable' leukemias show an average probability of about 70% survival at 3 yrs among adults less than 60 yrs of age. 35 . In this regard it is of note that in younger adults with favorable genotypes overall survival is similar between those who receive an allogeneic HSCT in first CR and those who do not so that in the good-risk patients the option of an allogeneic HSCT is usually reserved in case the leukemia will recur 33, 38, 39 . Also autologous stem cell transplant applied in CR1 reduces the probability of relapse with similar overall survival results
39
. The probability of attaining a second CR in AML with a favorable genetic profile is comparatively high which enhances the feasibility of salvage with an allotransplant in case of a relapse . 40 This probably holds similarly for patients with any favorable genotype, in particular the corebinding AMLs, AML with NPM1 mut/FLT3-ITD neg (nucleophosmin-1 gene mutation and absence of fms-like tyrosine kinase gene internal tandem duplications) 39 , AML with biallelic CEBPA mutants 38 . While autologous HSCT and allogeneic HSCT in younger and middleaged adults with favorable subtypes of AML offer about similar probabilities of overall survival, strictly speaking it is unknown whether these relationships can be extrapolated and hold up the same way in older patients. Thus in the patient presented here there are two defendable therapeutic strategies for consolidation in CR1, ie to apply chemotherapy or autologous HSCT and keep the option of an allogeneic HSCT as a back up for relapse, or
immediately proceed to an allogeneic HSCT. The downside of an allogeneic HSCT in CR1
obviously involves the risks of allo-immune mediated complications and greater mortality but on the other hand completion of the entire treatment within a single one-time concentrated intensive approach with a reduced risk of recurrence might be seen as an advantage. In any event, there is no compelling argument for guiding patients with low-risk AML to an early allogeneic HSCT in first CR. In the patient presented here based on the then available
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From knowledge the choice was made in favor of chemotherapy as first line treatment without a HSCT. Fortunately, our patient following the relapse readily entered a second CR which is quite characteristic for patients with favorable cytogenetic or molecular features 41 .
Patient 3-A 73-year-old man with AML with myelodysplasia-related changes: medical doubts about the feasibility of intensive chemotherapy.
A patient of 73 yrs old was admitted to our hospital with Hgb 5.9 mmol/l, platelets 53x10 9 /l, WBC 3. 
Comments about patient 3.
In this case the therapeutic decisions were dictated by performance status and co-morbidities.
The diagnosis of AML with myelodysplasia-related changes does not a priori classify as a bad prognostic leukemia. AML with myelodysplasia-related changes is very heterogenous and as 1 0 such it lacks independent prognostic significance. The prognosis is determined by underlying cytogenetic and molecular abnormalities. 42, 43 What are the possibilities in case a patient classifies as unfit or will not likely benefit from dose-intensive chemotherapy? Low dose cytarabine(LDAC) (20mg s.c. BID /10 days/4-6 weeks) is quite commonly employed in these patients in some countries but is less popular in other countries. Treatment with LDAC does not confer considerable toxicity and it produces a higher CR rate than best supportive care (18% vs 1%). 44 While the overall survival for the LDAC treated group has been demonstrated to be statistically significantly better, we should keep in mind that in absolute terms the therapeutic advantage is marginal and corresponds with a prolongation of overall survival of just a few months only. The benefit is restricted to the minority fraction of patients who achieve a CR (median survival 19 months versus 2 months in non-responders). 44 Furthermore, patients with adverse cytogenetics do not seem to benefit from LDAC. Thus the overall survival in patients receiving LDAC is still highly unsatisfactory (median 5 months). After extensive discussions with this intelligent and fit woman she declined the proposed option of intensive treatment. She elected to participate in a clinical study which enabled her to be treated in an outpatient setting. She was included in a pharmaceutical sponsored trial that prospectively compared LDAC alone with LDAC plus an investigational drug. She achieved a CR after 2 treatment cycles that now lasts for more than 12 months while she continues to receive treatment. She does not report any significant side effects.
Comments about patient 4
Although this patient would in our view have been suitable for intensive treatment she deliberately declined this option. Patients should be encouraged to participate in decision making based on accurate information about the risks and benefits of all available treatment options. Apart from chances of cure and treatment-related mortality, it should also include discussions on living and social circumstances, quality of life issues and personal expectations in relation to either choice 51 . In our patient individual socio-economic factors determined her decision and these then had to be taken into account to define the appropriate treatment. Since our patient was interested in receiving a less intensive treatment, there was an opportunity to enroll her in a clinical trial which whenever possible we would consider a priority option.
Final considerations
Today patients with AML at older age can be offered one of the following treatment options: Second, as an initial priority it seems useful to follow the same therapeutic principles that we apply in younger adults provided the medical situation of the patient allows for intensive induction chemotherapy. This implies that intensive remission induction chemotherapy is the first choice whenever this is considered realistic and feasible on clinical grounds. Early death is in most studies less than 15 % and does not seem to play a major role in the inferior outcome of elderly patients with AML. In this regard it is of note that the early death rate in intensively treated patients has decreased considerably over the last two decades most probably due to better supportive care. 21 A wait-and-see approach with supportive care and cytoreduction with hydroxyurea does not furnish a significantly better perspective for the patient with AML in terms of improving quality of life or prolonging survival since none of the basic medical problems will be tackled 28 .
Third, nonmyeloablative allogeneic HSCT being reasonably well tolerated in terms of early toxicity have shifted the age limit of the applicability alloHSCT upwards. Allogeneic HSCT following reduced intensity conditioning nowadays provides antileukemic effectiveness that is not much different from ablative alloHSCT.
Fourth, in a general sense the molecular features that characterize risk of AML in middle aged adults also apply to AML at older age 37 , although the incidence of unfavorable genotypes is significantly more frequent among older adults. These genetic disease-related features of the leukemia furnish clinically informative prognostic insights and thus may offer useful guidance along the way of the therapeutic management in an individual patient. For instance good-risk cytogenetics (core-binding factor leukemias) express a distinctly favorable impact in older patients with AML 3, 9 . And this background information may be reassuring in our management approach when we encounter intercurrent medical hurdles during the .
In this regard it should be noted that the frequencies of these genotypes are considerably less common in older patients 58 while the incidence of particular unfavorable genotypes (eg ASXL1 and TET2 gene mutations) appear to increase with progressively higher age 57, 59, 60, 61 .
Also gene expression levels have been evaluated for their prognostic value. They employ relative cutoff values (high versus low) rather than absolute values and therefore are more difficult to apply as a reference in clinical practice 62 . These accumulating genomic data mark the beginning of efforts to better understand and predict responsiveness and refractoriness to antileukemic drugs in individual patients. Testing so many emerging new drugs poses a real challenge and urges for new trial designs like the pick a winner concept that should offer the possibility of rationally designed combinations of new drugs. 63, 64 It would be desirable that major AML trial groups combine efforts in designing in close collaboration rational and complementing trials to accelerate the treatment development of AML that is so urgently needed.
Sixth, we would recommend whenever possible to include the older AML patients in well designed clinical trials. This furnishes some guarantee for quality of treatment (eg protocolized treatment according state of the art standards) but it also offers the opportunity to contribute to progress in this still devastating disease. 65 Especially the elderly unfit and at that point appears to show sufficient improvement so that an alloHSCT is considered feasible. For reasons discussed in the text, we recommend to include patients in a clinical trial whenever possible. Medical criteria and dilemmas regarding patient eligibility for intensive chemotherapy are also discussed in the manuscript. 
